Skip to main content

Chimeric antigen receptor (CAR) T-cell therapy against solid tumors by targeting the vasculature

Project description

Cell therapy targeting the tumour vasculature

Targeting the tumour vasculature is emerging as a promising anti-cancer treatment strategy. The scope of the EU-funded AngioCAR project is to develop an adoptive cell therapy based on chimeric antigen receptor (CAR) T cells directed against newly formed vessels in solid tumours. CAR T cells will carry antibodies against an extracellular form of the cytoskeletal protein vimentin encountered specifically in tumours. The vimentin-targeting CAR T cells will facilitate endothelial cell killing and also increase local inflammation, thereby reducing immune suppression. The AngioCAR approach alone or in combination with checkpoint inhibitors will open new possibilities for effective cancer therapy.


Net EU contribution
€ 175 572,48
De Boelelaan 1117
1081 HV Amsterdam

See on map

West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Research Organisations
Non-EU contribution
€ 0,00